
  
    
      
        Background_NNP
        A_DT wide_JJ range_NN of_IN symptoms_NNS produce_VBP considerable_JJ suffering_NN
        in_IN patients_NNS at_IN the_DT end_NN of_IN their_PRP$ lives_NNS ._. This_DT monograph_NN aims_VBZ
        to_TO summarize_VB the_DT core_NN competencies_NNS in_IN symptom_NN control_NN
        needed_VBN by_IN any_DT physician_NN ,_, no_DT matter_NN his_PRP$ or_CC her_PRP$ specialty_NN ._.
        Many_JJ of_IN the_DT approaches_NNS will_MD apply_VB much_JJ earlier_RBR in_IN the_DT
        course_NN of_IN the_DT illness_NN ,_, not_RB just_RB at_IN the_DT end_NN of_IN life_NN ._.
        The_DT monograph_NN does_VBZ not_RB purport_VBP to_TO summarize_VB specialist_NN
        knowledge_NN ._. While_IN some_DT practitioners_NNS will_MD have_VB specialist_NN
        palliative_JJ care_NN services_NNS upon_IN which_WDT to_TO call_VB ,_, most_JJS in_IN the_DT
        world_NN will_MD need_VB to_TO provide_VB the_DT initial_JJ approaches_NNS to_TO
        symptom_NN control_NN at_IN the_DT end-of-life_JJ ._. This_DT is_VBZ not_RB a_DT fringe_NN
        activity_NN ,_, but_CC a_DT core_NN competency_NN for_IN physicians_NNS ._. After_IN an_DT
        overview_NN of_IN the_DT approaches_NNS to_TO whole_JJ patient_NN assessment_NN ,_, we_PRP
        summarize_VB the_DT management_NN of_IN several_JJ of_IN the_DT more_RBR common_JJ
        symptoms_NNS that_WDT occur_VBP at_IN the_DT end-of-life_JJ ._.
        However_RB ,_, to_TO focus_VB on_IN symptom_NN control_NN skills_NNS alone_RB will_MD
        miss_VB the_DT mark_NN ._. To_TO be_VB effective_JJ in_IN end-of-life_JJ care_NN ,_,
        physicians_NNS must_MD also_RB have_VB a_DT broad_JJ conceptualization_NN of_IN
        end-of-life_JJ care_NN and_CC the_DT legal_JJ issues_NNS that_WDT support_NN it_PRP [_NN 1_CD ]_NN
        and_CC they_PRP must_MD be_VB competent_JJ in_IN communication_NN ,_,
        decision-making_NN and_CC relation-building_JJ skills_NNS [_NN 2_CD ]_NN ._. While_IN
        we_PRP hope_VBP each_DT pearl_NN can_MD improve_VB a_DT physician_NN 's_POS practice_NN ,_, the_DT
        complete_JJ 
        Education_NNP for_IN Physicians_NNPS on_IN End-of-life_NNP
        Care_NNP (_( EPEC_NNP )_) Curriculum_NNP should_MD be_VB mastered_VBN in_IN order_NN to_TO
        be_VB fully_RB effective_JJ ._. [_NN 3_CD ]_NN
      
      
        Methods_NNP
        To_TO increase_VB physician_NN knowledge_NN of_IN new_JJ developments_NNS in_IN
        palliation_NN and_CC their_PRP$ level_NN of_IN clinical_JJ competence_NN in_IN
        end-of-life_JJ care_NN ,_, the_DT Institute_NNP for_IN Ethics_NNP at_IN the_DT American_NNP
        Medical_NNP Association_NNP ,_, with_IN support_NN from_IN the_DT Robert_NNP Wood_NNP
        Johnson_NNP Foundation_NNP ,_, embarked_VBD on_IN the_DT Education_NNP for_IN
        Physicians_NNPS on_IN End-of-life_NNP Care_NNP (_( EPEC_NNP )_) Project_NN ._. The_DT overall_JJ
        goal_NN of_IN the_DT EPEC_NNP Project_NNP is_VBZ to_TO teach_VB physicians_NNS how_WRB to_TO
        provide_VB better_JJR care_NN to_TO terminally_RB ill_JJ patients_NNS ._. The_DT overall_JJ
        method_NN is_VBZ to_TO use_VB a_DT "_'' train-the-trainer_JJ "_'' dissemination_NN model_NN ._.
        The_DT central_JJ hypothesis_NNS is_VBZ that_IN a_DT core_NN curriculum_NN designed_VBD ,_,
        written_VBN and_CC taught_VBN by_IN physicians_NNS using_VBG state_NN of_IN the_DT art_NN
        clinical_JJ knowledge_NN and_CC education_NN theory_NN ,_, can_MD be_VB effective_JJ
        in_IN reaching_VBG a_DT second_JJ tier_NN of_IN physicians_NNS by_IN having_VBG the_DT newly_RB
        trained_VBN physicians_NNS return_VBP to_TO their_PRP$ work_NN settings_NNS and_CC seek_VB
        to_TO engage_VB and_CC educate_VB a_DT growing_VBG number_NN of_IN their_PRP$ peers_NNS using_VBG
        and_CC adapting_VBG the_DT provided_VBN educational_JJ materials_NNS ._. The_DT
        project_NN aims_VBZ to_TO improve_VB end-of-life_JJ care_NN through_IN a_DT ripple_NN
        effect_NN as_IN the_DT trainers_NNS educate_VB a_DT growing_VBG number_NN of_IN
        physicians_NNS ._.
        A_DT key_JJ tool_NN of_IN the_DT EPEC_NNP Project_NNP was_VBD the_DT development_NN of_IN
        the_DT 
        EPEC_NNP Curriculum_NNP ._. It_PRP sets_VBZ out_RP the_DT core_NN
        competencies_NNS that_IN all_DT physicians_NNS should_MD have_VB in_IN palliative_JJ
        care_NN ._. It_PRP was_VBD not_RB intended_VBN to_TO define_VB or_CC describe_VB the_DT
        specialty_NN skills_NNS of_IN a_DT palliative_JJ medicine_NN physician_NN ._. Two_CD
        Advisory_NNP Boards_NNP of_IN 24_CD expert_NN physicians_NNS in_IN ethics_NNS ,_, hospice_NN ,_,
        and_CC palliative_JJ care_NN initially_RB recommended_VBD the_DT curricular_NN
        content_NN and_CC format_NN ._. A_DT team_NN of_IN experts_NNS with_IN considerable_JJ
        clinical_JJ and_CC research_NN experience_NN and_CC expertise_NN in_IN physician_NN
        education_NN then_RB developed_VBD the_DT curriculum_NN ._. Finally_RB ,_, it_PRP was_VBD
        modified_VBN based_VBN on_IN the_DT opinions_NNS of_IN the_DT first_JJ 280_CD physicians_NNS
        and_CC other_JJ health_NN care_NN professionals_NNS trained_VBN to_TO teach_VB
        end-of-life_JJ care_NN using_VBG the_DT 
        EPEC_NNP Curriculum_NNP (_( EPEC_NNP Trainers_NNP )_) ._. The_DT
        final_JJ 
        EPEC_NNP Curriculum_NNP represents_VBZ a_DT
        synthesis_NN of_IN the_DT ideas_NNS of_IN many_JJ experts_NNS and_CC clinicians_NNS ._. The_DT
        information_NN in_IN the_DT present_JJ manuscript_NN is_VBZ extracted_VBN from_IN
        this_DT curriculum_NN
      
      
        Results_NNS
        
          Whole_JJ Patient_NNP Assessment_NNP
          Management_NN strategies_NNS to_TO relieve_VB suffering_VBG in_IN
          end-of-life_JJ care_NN begin_VB with_IN a_DT comprehensive_JJ assessment_NN of_IN
          the_DT whole_JJ patient_NN ,_, and_CC his_PRP$ or_CC her_PRP$ family_NN ._. This_DT approach_NN
          to_TO assessment_NN may_MD be_VB quite_RB distinct_JJ from_IN familiar_JJ history_NN
          taking_NN and_CC physical_JJ examination_NN techniques_NNS ._. Whole_JJ patient_NN
          assessment_NN examines_VBZ a_DT range_NN of_IN issues_NNS that_WDT may_MD cause_VB
          suffering_VBG ._. It_PRP forms_VBZ the_DT basis_NN for_IN setting_VBG goals_NNS of_IN care_NN
          rather_RB than_IN seeking_VBG problem-based_JJ solutions_NNS ._. The_DT
          assessment_NN process_NN itself_PRP can_MD be_VB a_DT therapeutic_JJ tool_NN ._. It_PRP
          acknowledges_VBZ the_DT patient_NN as_IN a_DT person_NN ,_, and_CC conveys_VBZ
          compassion_NN ._. [_NN 4_CD 5_CD 6_CD ]_NN
          During_IN the_DT assessment_NN ,_, ask_VB about_IN each_DT of_IN the_DT possible_JJ
          symptoms_NNS and_CC the_DT patient_NN 's_POS functional_JJ activities_NNS ,_, rather_RB
          than_IN about_IN organ_NN systems_NNS or_CC anatomy_NN ._. Because_IN symptoms_NNS are_VBP
          inherently_RB subjective_JJ ,_, patient_JJ self-report_JJ is_VBZ the_DT gold_NN
          standard_JJ for_IN assessment_NN [_NN 7_CD ]_NN ._. Validated_NNP symptom_NN
          assessment_NN tools_NNS may_MD assist_VB the_DT clinician_NN to_TO gain_VB
          consistent_JJ insight_NN into_IN the_DT patient_NN 's_POS perception_NN of_IN a_DT
          symptom_NN (_( eg_NN ,_, its_PRP$ severity_NN ,_, etc_FW )_) ._. When_WRB considering_VBG
          diagnostic_JJ tests_NNS ,_, assess_VB their_PRP$ potential_JJ to_TO assist_VB relief_NN
          of_IN suffering_VBG rather_RB than_IN diagnosis_NN for_IN its_PRP$ own_JJ sake_NN ._.
          Most_JJS people_NNS with_IN an_DT advanced_VBN life-threatening_JJ illness_NN
          experience_NN situational_NN and_CC possibly_RB pathological_JJ changes_NNS
          in_IN their_PRP$ affect_NN and_CC cognitive_JJ function_NN ,_, and_CC a_DT range_NN of_IN
          emotions_NNS and_CC fears_NNS ._. Fear_NN of_IN loss_NN of_IN control_NN and_CC dignity_NN ,_,
          abandonment_NN ,_, being_VBG a_DT burden_NN ,_, and_CC physical_NN suffering_NN can_MD
          be_VB so_RB strong_JJ that_IN patients_NNS desire_VBP hastened_VBN death_NN ._.
          Screening_NNP questions_NNS to_TO assess_VB for_IN depression_NN ,_, anxiety_NN and_CC
          cognitive_JJ impairment_NN ,_, and_CC inquiries_NNS about_IN coping_VBG
          responses_NNS and_CC fears_NNS ,_, are_VBP all_DT important_JJ since_IN these_DT issues_NNS
          can_MD be_VB redressed_JJ [_NN 8_CD 9_CD ]_NN ._.
          While_IN the_DT physician_NN may_MD not_RB have_VB the_DT skills_NNS of_IN a_DT
          social_JJ worker_NN ,_, he_PRP or_CC she_PRP should_MD be_VB able_JJ to_TO make_VB an_DT
          initial_JJ assessment_NN of_IN the_DT patient_NN 's_POS social_JJ and_CC practical_JJ
          needs_NNS ._. Unresolved_NNP relationships_NNS or_CC financial_JJ ,_, legal_JJ ,_, or_CC
          practical_JJ matters_NNS may_MD be_VB sources_NNS of_IN distress_NN [_NN 10_CD ]_NN ._.
          Because_IN 30_CD %_NN of_IN families_NNS spend_VBP their_PRP$ life_NN savings_NNS and_CC /_NN or_CC
          lose_VB a_DT source_NN of_IN income_NN in_IN order_NN to_TO care_VB for_IN the_DT patient_NN ,_,
          it_PRP is_VBZ important_JJ to_TO know_VB about_IN financial_JJ status_NN and_CC health_NN
          insurance_NN coverage_NN [_NN 11_CD ]_NN ._. The_DT need_NN for_IN practical_JJ help_NN
          must_MD be_VB addressed_VBN ;_: even_RB the_DT best_JJS of_IN care_NN plans_NNS may_MD fail_VB
          if_IN the_DT chores_NNS of_IN day-to-day_JJ living_NN are_VBP not_RB attended_VBN to_TO [_NN
          12_CD ]_NN ._.
          Every_DT person_NN has_VBZ a_DT spiritual_NN dimension_NN to_TO his_PRP$ or_CC her_PRP$
          life_NN ._. Whether_IN it_PRP is_VBZ understood_VBN in_IN frankly_RB religious_JJ
          terms_NNS ,_, or_CC in_IN terms_NNS of_IN personal_JJ meaning_NN and_CC the_DT mystery_NN of_IN
          life_NN ,_, studies_NNS suggest_VBP that_WDT patients_NNS welcome_JJ inquiry_NN about_IN
          their_PRP$ spiritual_NN issues_NNS [_NN 13_CD 14_CD ]_NN ._. While_IN a_DT chaplain_NN or_CC
          skilled_JJ pastor_NN usually_RB administers_VBZ spiritual_NN care_NN ,_, the_DT
          physician_NN must_MD consider_VB the_DT possibility_NN that_DT spiritual_NN
          pain_NN also_RB manifests_NNS itself_PRP as_IN physical_JJ ,_, mental_JJ ,_, or_CC social_JJ
          distress_NN ._.
          Equipped_VBN with_IN a_DT full_JJ assessment_NN of_IN the_DT nature_NN and_CC
          context_NN of_IN the_DT issues_NNS that_WDT are_VBP causing_VBG suffering_VBG for_IN the_DT
          patient_NN and_CC family_NN ,_, the_DT physician_NN can_MD then_RB address_VB each_DT
          issue_NN in_IN turn_NN ._. The_DT following_VBG addresses_NNS some_DT of_IN the_DT most_RBS
          common_JJ physical_JJ issues_NNS and_CC some_DT touches_NNS on_IN some_DT of_IN the_DT
          related_VBN family_NN or_CC social_JJ issues_NNS they_PRP raise_VBP ._.
        
        
          Pain_NNP
          Pain_NNP occurs_VBZ frequently_RB in_IN end-of-life_JJ care_NN ._. It_PRP can_MD be_VB
          acute_JJ or_CC chronic_JJ [_NN 15_CD ]_NN ._.
          Pain_NNP can_MD be_VB nociceptive_JJ or_CC neuropathic_JJ in_IN origin_NN ._. The_DT
          patient_NN 's_POS description_NN ,_, physical_JJ findings_NNS ,_, and_CC the_DT results_NNS
          of_IN laboratory_NN tests_NNS and_CC imaging_NN studies_NNS will_MD usually_RB be_VB
          sufficient_JJ for_IN a_DT provisional_JJ diagnosis_NN [_NN 16_CD ]_NN ._.
          Nociceptive_NNP pain_NN involves_VBZ direct_JJ stimulation_NN of_IN intact_JJ
          mechanical_JJ ,_, chemical_NN ,_, or_CC thermal_JJ nociceptors_NNS ,_, and_CC
          transmission_NN of_IN electrical_JJ signals_NNS along_IN normally_RB
          functioning_VBG nerves_NNS ._. Patients_NNS may_MD describe_VB this_DT as_IN sharp_JJ ,_,
          aching_VBG ,_, and_CC /_NN or_CC throbbing_VBG pain_NN that_WDT is_VBZ easily_RB localized_JJ ._.
          Visceral_NNP nociceptive_JJ pain_NN (_( eg_NN ,_, cardiac_JJ ,_, lung_NN ,_, GI_NNP ,_, GU_NNP )_)
          results_NNS from_IN stimulation_NN of_IN the_DT autonomic_JJ nervous_JJ system_NN
          and_CC may_MD be_VB difficult_JJ to_TO describe_VB or_CC localize_NN ._.
          Neuropathic_NNP pain_NN is_VBZ presumed_VBN to_TO result_VB from_IN disordered_JJ
          function_NN of_IN the_DT peripheral_JJ or_CC central_JJ nervous_JJ system_NN due_JJ
          to_TO any_DT of_IN many_JJ potential_JJ causes_NNS ._. Patients_NNS tend_VBP to_TO
          describe_VB neuropathic_JJ pain_NN with_IN words_NNS like_IN burning_NN ,_,
          tingling_VBG ,_, numbness_NNS ,_, shooting_VBG ,_, stabbing_VBG ,_, or_CC electric-like_JJ
          feelings_NNS ._.
        
        
          Management_NNP
          Effective_NNP pain_NN management_NN requires_VBZ a_DT clear_JJ
          understanding_NN of_IN the_DT etiology_NN and_CC neuropathophysiology_NN of_IN
          each_DT pain_NN ,_, and_CC the_DT pharmacology_NN of_IN analgesics_NNS ._.
          Nociceptive_NNP pain_NN generally_RB responds_VBZ well_RB to_TO opioids_NNS
          and_CC /_NN or_CC coanalgesics_NNS ._. Although_IN neuropathic_JJ pain_NN may_MD
          respond_VB well_RB to_TO opioids_NNS ,_, adjuvant_NN analgesics_NNS (_( tricyclic_JJ
          antidepressants_NNS ,_, anticonvulsants_NNS ,_, antiarrhythmics_NNS ,_, etc_FW )_)
          are_VBP often_RB required_VBN in_IN combination_NN with_IN opioids_NNS to_TO achieve_VB
          adequate_JJ relief_NN ._.
          Although_IN research_NN is_VBZ not_RB yet_RB conclusive_JJ ,_, unmanaged_JJ
          pain_NN itself_PRP may_MD lead_VB to_TO changes_NNS in_IN the_DT nervous_JJ system_NN
          that_WDT could_MD reduce_VB its_PRP$ responsiveness_NNS to_TO treatment_NN ._. [_NN 17_CD
          18_CD 19_CD ]_NN Equally_RB important_JJ ,_, unrelieved_JJ pain_NN can_MD have_VB a_DT
          devastating_JJ psychological_JJ effect_NN on_IN the_DT individual_NN and_CC
          family_NN [_NN 20_CD ]_NN ._. As_IN there_EX is_VBZ no_DT reason_NN to_TO delay_VB the_DT use_NN of_IN
          analgesics_NNS ,_, [_NN 16_CD ]_NN initiate_NN analgesic_JJ interventions_NNS while_IN
          completing_VBG investigations_NNS and_CC providing_VBG therapies_NNS
          directed_VBN against_IN the_DT cause_NN of_IN the_DT pain_NN (_( eg_NN ,_, radiation_NN for_IN
          a_DT neoplasm_NN )_) ._.
          Placebos_NNP have_VBP no_DT role_NN to_TO play_VB in_IN the_DT assessment_NN or_CC
          management_NN of_IN pain_NN outside_IN of_IN clinical_JJ trials_NNS [_NN 21_CD ]_NN ._.
          Neither_DT is_VBZ there_RB rationale_NN for_IN concerns_NNS that_IN appropriate_JJ
          doses_NNS of_IN analgesics_NNS will_MD "_'' mask_NN "_'' signs_NNS that_WDT will_MD prevent_VB
          accurate_JJ diagnosis_NN and_CC treatment_NN [_NN 22_CD 23_CD 24_CD ]_NN ._.
          Frequently_RB ,_, pharmacological_JJ and_CC non-pharmacological_JJ
          interventions_NNS and_CC an_DT interdisciplinary_JJ plan_NN that_WDT includes_VBZ
          other_JJ health_NN care_NN professionals_NNS (_( nurses_NNS ,_, social_JJ workers_NNS ,_,
          pharmacists_NNS ,_, chaplains_NNS ,_, physiotherapists_NNS ,_, occupational_NN
          therapists_NNS ,_, child_NN life_NN specialists_NNS ,_, etc_FW )_) are_VBP required_VBN to_TO
          manage_VB pain_NN effectively_RB ._. Plans_NNS must_MD be_VB tailored_VBN to_TO the_DT
          expectations_NNS and_CC needs_NNS of_IN each_DT individual_JJ patient_NN and_CC
          family_NN ._. Flexibility_NNP and_CC ongoing_JJ education_NN of_IN the_DT patient_NN ,_,
          family_NN ,_, and_CC all_DT caregivers_NNS ,_, ongoing_JJ assessment_NN of_IN
          treatment_NN outcomes_NNS ,_, and_CC regular_JJ review_NN of_IN the_DT plan_NN of_IN
          care_NN are_VBP all_DT essential_JJ [_NN 15_CD 16_CD ]_NN ._. When_WRB a_DT plan_NN does_VBZ not_RB
          control_VB a_DT patient_NN 's_POS pain_NN in_IN a_DT timely_JJ manner_NN ,_, ask_VB for_IN help_NN
          from_IN colleagues_NNS with_IN more_JJR expertise_NN ._.
        
        
          WHO_WP 3_CD -_: Step_NN Model_NNP to_TO Guide_NNP Analgesic_NNP Dosing_NNP
          In_IN 1986_CD ,_, the_DT World_NNP Health_NNP Organization_NNP (_( WHO_WP )_) developed_VBD
          a_DT 3_CD -_: step_NN conceptual_JJ model_NN to_TO guide_VB the_DT management_NN of_IN
          cancer_NN pain_NN (_( see_VB Figure_NN 1_LS )_) [_NN 25_CD ]_NN ._. It_PRP provides_VBZ a_DT simple_JJ ,_,
          well-tested_JJ model_NN to_TO guide_VB the_DT initial_JJ selection_NN ,_,
          administration_NN ,_, and_CC titration_NN of_IN analgesics_NNS to_TO manage_VB the_DT
          pain_NN associated_VBN with_IN any_DT serious_JJ illness_NN ._. When_WRB initiating_VBG
          or_CC titrating_VBG analgesics_NNS ,_, it_PRP is_VBZ not_RB necessary_JJ to_TO traverse_NN
          each_DT step_NN of_IN the_DT model_NN sequentially_RB ;_: a_DT patient_NN with_IN
          severe_JJ pain_NN (_( 7_CD -_: 10_CD /_NN 10_CD on_IN a_DT numerical_JJ or_CC visual_JJ analogue_NN
          scale_NN -_: NAS_NNP or_CC VAS_NNP )_) may_MD need_VB to_TO have_VB step_NN 3_CD opioids_NNS from_IN
          the_DT outset_NN ._.
        
        
          Step_NN 1_CD Analgesics_NNP
          Acetaminophen_NNP and_CC the_DT non-steroidal_JJ anti-inflammatory_JJ
          drugs_NNS (_( NSAIDs_NNP ,_, including_VBG ASA_NNP )_) have_VBP an_DT important_JJ role_NN in_IN
          symptom_NN management_NN ._. However_RB ,_, all_DT have_VBP a_DT ceiling_NN effect_NN to_TO
          their_PRP$ analgesia_NN (_( See_VB table_NN 1_LS )_) [_NN 25_CD ]_NN ._. All_DT step_NN 1_CD
          analgesics_NNS have_VBP a_DT risk_NN of_IN adverse_JJ effects_NNS that_WDT are_VBP
          potentially_RB life-threatening_JJ ._.
          The_DT mechanism_NN of_IN action_NN of_IN acetaminophen_NN is_VBZ still_RB
          unknown_JJ (_( although_IN it_PRP is_VBZ known_VBN that_IN it_PRP does_VBZ not_RB have_VB a_DT
          peripheral_JJ anti-inflammatory_JJ effect_NN )_) ._. Typically_RB ,_, it_PRP is_VBZ
          used_VBN alone_RB or_CC combined_VBN with_IN other_JJ analgesics_NNS (_( as_IN a_DT
          coanalgesic_JJ for_IN additive_JJ or_CC synergistic_JJ analgesic_JJ
          effects_NNS )_) ._. Patients_NNS who_WP may_MD think_VB more_JJR is_VBZ better_JJR should_MD be_VB
          cautioned_VBD that_DT toxicity_NN can_MD ensue_VB at_IN >_NN 4_CD gm_NN
          acetaminophen_NN /_NN 24_CD hr_NN ,_, particularly_RB in_IN patients_NNS with_IN
          hepatic_JJ compromise_NN ._.
          NSAIDs_NNP work_NN ,_, at_IN least_JJS in_IN part_NN ,_, by_IN inhibiting_VBG
          cyclo-oxygenase_JJ ,_, the_DT enzyme_NN that_WDT converts_VBZ arachidonic_JJ
          acid_NN to_TO prostaglandins_NNS ._. They_PRP act_VBP directly_RB at_IN
          neuro-synaptic_JJ junctions_NNS and_CC by_IN reducing_VBG inflammation_NN ._.
          They_PRP can_MD be_VB used_VBN alone_RB ,_, or_CC as_IN coanalgesics_NNS ._.
          Extended-release_NNP NSAIDs_NNP ,_, or_CC those_DT with_IN long_JJ half-lives_JJ
          (_( eg_NN ,_, piroxicam_NN )_) ,_, are_VBP likely_JJ to_TO enhance_VB adherence_NN ._.
          Intravenous_NNP formulations_NNS are_VBP also_RB available_JJ (_( eg_NN ,_,
          ketorolac_NN )_) ._. Care_NNP must_MD be_VB taken_VBN to_TO anticipate_VB the_DT
          potentially_RB adverse_JJ effects_NNS of_IN NSAIDs_NNP (_( eg_NN ,_, gastropathy_NN ,_,
          nephropathy_NN and_CC inhibition_NN of_IN platelet_NN aggregation_NN )_) that_WDT
          are_VBP independent_JJ of_IN the_DT route_NN of_IN administration_NN ._. The_DT newer_JJR
          agents_NNS specific_JJ to_TO the_DT isoenzyme_NN cyclo-oxygenase_JJ 2_CD may_MD
          have_VB fewer_RBR adverse_JJ effects_NNS ,_, but_CC are_VBP less_RBR potent_JJ and_CC more_RBR
          expensive_JJ than_IN other_JJ possible_JJ choices_NNS ._. There_EX is_VBZ no_DT reason_NN
          not_RB to_TO start_VB with_IN the_DT least_JJS expensive_JJ agent_NN for_IN a_DT
          clinical_JJ trial_NN before_IN moving_VBG to_TO more_RBR expensive_JJ
          agents_NNS ._.
        
        
          Step_NN 2_CD and_CC 3_CD Analgesics_NNP
          Step_NN 2_CD and_CC 3_CD analgesics_NNS include_VBP the_DT pure_JJ agonist_NN
          opioids_NNS ,_, eg_NN ,_, codeine_NN ,_, fentanyl_NN ,_, hydrocodone_NN ,_,
          hydromorphone_NN ,_, morphine_NN ,_, and_CC oxycodone_NN ._. Those_DT suggested_VBD
          for_IN step_NN 2_CD dosing_VBG combine_VB a_DT pure_JJ agonist_NN opioid_NN with_IN
          either_DT acetaminophen_NN or_CC aspirin_NN to_TO limit_VB the_DT amount_NN of_IN
          opioid_NN that_WDT can_MD be_VB used_VBN [_NN 25_CD ]_NN ._.
          All_DT of_IN these_DT opioids_NNS except_IN fentanyl_NN follow_VB
          first-order_JJ kinetics_NNS ._. They_PRP reach_VBP their_PRP$ peak_NN plasma_NN
          concentration_NN (_( Cmax_NNP )_) approximately_RB 60_CD to_TO 90_CD minutes_NNS after_IN
          oral_JJ (_( including_VBG enteral_NN feeding_NN tube_NN )_) or_CC rectal_NN
          administration_NN ,_, 30_CD minutes_NNS after_IN subcutaneous_JJ or_CC
          intramuscular_NN injection_NN ,_, and_CC 6_CD minutes_NNS after_IN intravenous_JJ
          injection_NN (_( see_VB Figure_NN 2_LS )_) ._. Dosed_NNP once_RB every_DT half-life_NN ,_,
          steady_JJ state_NN plasma_NN concentrations_NNS are_VBP achieved_VBN within_IN
          4_CD -_: 5_CD half-lives_JJ ._. Analgesia_NNP appears_VBZ to_TO track_VB with_IN plasma_NN
          concentration_NN ._. They_PRP are_VBP eliminated_VBN from_IN the_DT body_NN at_IN a_DT
          fixed_VBN rate_NN irrespective_RB of_IN the_DT dose_NN ._. The_DT liver_NN first_RB
          conjugates_NNS them_PRP ,_, then_RB the_DT kidney_NN excretes_NNS 90_CD %_NN to_TO 95_CD %_NN of_IN
          the_DT metabolites_NNS ._. Except_IN for_IN the_DT demethylation_NN of_IN codeine_NN
          (_( methylmorphine_NN )_) to_TO its_PRP$ active_JJ metabolite_NN ,_, their_PRP$
          metabolic_JJ pathways_NNS do_VBP not_RB become_VB saturated_VBD ._.
          Based_VBN on_IN these_DT pharmacological_JJ principles_NNS ,_, if_IN an_DT
          immediate-acting_JJ oral_JJ opioid_NN is_VBZ selected_VBN and_CC the_DT pain_NN is_VBZ
          continuous_JJ ,_, or_CC nearly_RB so_RB ,_, give_VBP the_DT medication_NN q_NN 4_CD h_NN on_IN a_DT
          routine_JJ schedule_NN (_( not_RB "_'' as_RB needed_VBN "_'' )_) ._. The_DT best_JJS possible_JJ
          pain_NN control_NN for_IN the_DT dose_NN will_MD be_VB achieved_VBN within_IN 24_CD
          hours_NNS ,_, once_RB steady_JJ state_NN has_VBZ been_VBN reached_VBN ._.
          To_TO control_VB any_DT extra_JJ or_CC "_'' breakthrough_NN "_'' pain_NN ,_, provide_VBP
          the_DT patient_NN with_IN "_'' as_RB needed_VBN "_'' rescue_NN doses_NNS of_IN the_DT same_JJ
          immediate-acting_JJ opioid_NN ._. Each_DT rescue_NN dose_NN should_MD be_VB about_IN
          10_CD -_: 20_CD %_NN of_IN the_DT total_JJ 24_CD hour_NN dose_NN ,_, offered_VBN q_NN 1_CD h_NN prn_NN PO_NNP or_CC
          PR_NNP ,_, q_NN 30_CD min_NN prn_NN SC_NNP or_CC IM_NNP ,_, or_CC q_NN 10_CD -_: 15_CD min_NN prn_NN IV_NNP ._.
          If_IN pain_NN remains_VBZ uncontrolled_JJ after_IN 24_CD hours_NNS ,_, increase_NN
          the_DT routine_JJ dose_NN by_IN an_DT amount_NN at_IN least_JJS equal_JJ to_TO the_DT total_JJ
          dose_NN of_IN rescue_NN medication_NN used_VBN during_IN the_DT previous_JJ 24_CD
          hours_NNS ._. If_IN pain_NN is_VBZ mild_JJ or_CC moderate_JJ ,_, an_DT increase_NN of_IN 25_CD %_NN to_TO
          50_CD %_NN in_IN the_DT total_JJ daily_JJ dose_NN should_MD be_VB expected_VBN ._. If_IN pain_NN
          is_VBZ severe_JJ or_CC uncontrolled_JJ ,_, an_DT increase_NN of_IN 50_CD %_NN to_TO 100_CD %_NN
          should_MD be_VB expected_VBN ._. In_IN fact_NN ,_, if_IN pain_NN is_VBZ severe_JJ and_CC
          uncontrolled_JJ after_IN 1_CD or_CC 2_CD doses_NNS (_( eg_NN ,_, crescendo_NN pain_NN )_) ,_, do_VBP
          not_RB wait_VB for_IN 24_CD hours_NNS to_TO pass_VB before_IN increasing_VBG the_DT
          routine_JJ dose_NN ._. There_EX is_VBZ no_DT maximum_NN dose_NN for_IN a_DT pure_JJ agonist_NN
          opioid_NN ._. Follow_VB the_DT patient_NN closely_RB and_CC titrate_NN the_DT
          analgesics_NNS until_IN the_DT pain_NN is_VBZ relieved_VBN or_CC adverse_JJ effects_NNS
          are_VBP encountered_VBN ._.
          Increasingly_RB ,_, 12_CD -_: 24_CD hours_NNS sustained-release_JJ
          formulations_NNS of_IN the_DT opioids_NNS are_VBP becoming_VBG widely_RB available_JJ
          for_IN routine_JJ usage_NN ,_, either_CC as_IN tablets_NNS or_CC granules_NNS ._. They_PRP
          must_MD be_VB ingested_JJ whole_NN ,_, not_RB crushed_VBN or_CC chewed_VBD ._. A_DT fentanyl_NN
          transdermal_NN patch_NN is_VBZ also_RB available_JJ that_WDT can_MD deliver_VB
          medication_NN for_IN up_IN to_TO 72_CD hours_NNS ._. Use_NN of_IN these_DT preparations_NNS
          is_VBZ likely_JJ to_TO improve_VB patient_NN adherence_NN ._. Extended-release_NNP
          formulations_NNS are_VBP not_RB indicated_VBN for_IN rescue_NN dosing_VBG ._. For_IN
          this_DT purpose_NN ,_, use_NN a_DT concurrent_JJ dose_NN of_IN an_DT
          immediate-release_JJ formulation_NN of_IN the_DT same_JJ opioid_NN ._.
          Methadone_NNP ,_, although_IN the_DT least_JJS expensive_JJ oral_JJ opioid_NN ,_,
          has_VBZ a_DT long_JJ and_CC variable_JJ half-life_NN (_( days_NNS )_) ._. Only_RB those_DT with_IN
          additional_JJ training_NN should_MD use_VB it_PRP for_IN pain_NN control_NN ._.
          Not_RB all_DT opioid_NN analgesics_NNS that_WDT are_VBP commonly_RB available_JJ
          are_VBP recommended_VBN for_IN acute_JJ or_CC chronic_NN dosing_VBG ._. Meperidine_NNP
          is_VBZ poorly_RB absorbed_VBN orally_RB and_CC has_VBZ a_DT short_JJ half-life_NN of_IN
          approximately_RB 2_CD -_: 3_CD hours_NNS ._. Its_PRP$ principal_JJ metabolite_NN ,_,
          normeperidine_NN ,_, has_VBZ no_DT analgesic_JJ properties_NNS of_IN its_PRP$ own_JJ ,_,
          has_VBZ a_DT longer_JJR half-life_NN of_IN about_IN 6_CD hours_NNS ,_, is_VBZ renally_RB
          excreted_JJ ,_, and_CC produces_VBZ significant_JJ adverse_JJ effects_NNS when_WRB
          it_PRP accumulates_NNS ._. Propoxyphene_NNP is_VBZ typically_RB administered_VBN at_IN
          doses_NNS that_WDT produce_VBP relatively_RB little_JJ analgesia_NN ._. The_DT mixed_JJ
          opioid_NN agonist-antagonists_JJ such_JJ as_IN pentazocine_NN ,_,
          butorphanol_NN ,_, nalbuphine_NN ,_, and_CC dezocine_NN are_VBP not_RB recommended_VBN
          as_IN routine_JJ analgesics_NNS ._. Their_PRP$ dosing_VBG is_VBZ limited_VBN by_IN a_DT
          ceiling_NN effect_NN ,_, and_CC they_PRP have_VBP a_DT high_JJ risk_NN of_IN adverse_JJ
          effects_NNS ._. They_PRP must_MD not_RB be_VB used_VBN if_IN the_DT patient_NN is_VBZ already_RB
          taking_VBG a_DT pure_JJ agonist_NN opioid_NN ,_, as_IN competition_NN for_IN the_DT
          opioid_NN receptors_NNS may_MD cause_VB a_DT withdrawal_NN syndrome_NN ._.
          If_IN patients_NNS have_VBP good_JJ pain_NN control_NN on_IN stable_JJ doses_NNS of_IN
          an_DT opioid_NN ,_, and_CC are_VBP not_RB experiencing_VBG adverse_JJ effects_NNS
          (_( especially_RB drowsiness_NNS )_) ,_, it_PRP is_VBZ safe_JJ to_TO drive_VB a_DT car_NN ._.
          Patients_NNS in_IN pain_NN may_MD have_VB much_RB poorer_JJR reaction_NN times_NNS and_CC
          may_MD be_VB a_DT much_RB greater_JJR risk_NN ._.
          If_IN a_DT patient_NN is_VBZ unable_JJ to_TO ingest_VB an_DT oral_JJ analgesic_JJ an_DT
          alternate_JJ route_NN of_IN administration_NN or_CC an_DT alternate_JJ opioid_NN
          may_MD be_VB preferable_JJ ._. Intramuscular_NNP injections_NNS are_VBP not_RB
          recommended_VBN ._. Intermittent_NNP subcutaneous_JJ doses_NNS are_VBP just_RB as_IN
          effective_JJ ,_, and_CC much_RB less_RBR painful_JJ ._.
          When_WRB changing_VBG routes_NNS of_IN administration_NN or_CC opioids_NNS ,_, an_DT
          equianalgesic_JJ table_NN is_VBZ a_DT useful_JJ guide_NN for_IN initial_JJ dose_NN
          selection_NN ._. Significant_JJ first-pass_JJ metabolism_NN necessitates_NNS
          larger_JJR oral_JJ or_CC rectal_NN doses_NNS to_TO produce_VB analgesia_NN
          equivalent_JJ to_TO parenteral_NN doses_NNS of_IN the_DT same_JJ opioid_NN ._.
          Equivalence_NNP dosing_VBG recommendations_NNS represent_VBP consensus_NN
          from_IN limited_JJ available_JJ evidence_NN ,_, so_IN they_PRP are_VBP guides_NNS only_RB ._.
          Individual_JJ patients_NNS may_MD require_VB doses_NNS to_TO be_VB adjusted_VBN by_IN
          more_JJR than_IN a_DT factor_NN of_IN 2_CD to_TO achieve_VB effective_JJ analgesia_NN
          without_IN adverse_JJ effects_NNS (_( See_VB Table_NNP 2_LS )_) [_NN 26_CD ]_NN ._.
          Opioids_NNP have_VBP common_JJ and_CC uncommon_JJ adverse_JJ effects_NNS
          (_( Table_NNP 3_LS )_) ._. While_IN several_JJ may_MD be_VB a_DT problem_NN initially_RB ,_,
          pharmacological_JJ tolerance_NN typically_RB develops_VBZ to_TO all_DT of_IN
          the_DT adverse_JJ effects_NNS except_IN constipation_NN within_IN days_NNS ._.
          Always_RB caution_NN patients_NNS and_CC families_NNS to_TO anticipate_VB nausea_NN
          and_CC drowsiness_NNS for_IN the_DT first_JJ few_JJ days_NNS until_IN tolerance_NN
          develops_VBZ ._. Provide_VB antiemetics_NNS as_IN needed_VBN ._. Prophylactic_NNP
          routine_JJ stimulant_NN laxatives_NNS should_MD be_VB prescribed_VBN ._.
          Many_JJ physicians_NNS misperceive_JJ that_IN respiratory_JJ
          depression_NN is_VBZ a_DT significant_JJ risk_NN when_WRB prescribing_VBG opioids_NNS
          for_IN pain_NN ._. In_IN fact_NN ,_, it_PRP is_VBZ rare_JJ :_: pain_NN is_VBZ a_DT potent_JJ stimulus_NN
          to_TO breath_NN ,_, somnolence_NN always_RB develops_VBZ first_JJ ,_, and_CC
          pharmacological_JJ tolerance_NN to_TO respiratory_JJ depression_NN
          develops_VBZ quickly_RB ._.
          The_DT cost_NN of_IN opioid_NN analgesics_NNS varies_VBZ considerably_RB ._.
          Adequate_NNP analgesia_NN can_MD be_VB achieved_VBN for_IN the_DT majority_NN of_IN
          patients_NNS with_IN the_DT least_JJS expensive_JJ opioids_NNS such_JJ as_IN
          immediate-release_JJ preparations_NNS of_IN morphine_NN ._.
        
        
          Addiction_NNP
          It_PRP is_VBZ a_DT prevalent_JJ myth_NN that_IN the_DT administration_NN of_IN
          opioid_NN analgesics_NNS for_IN pain_NN management_NN causes_NNS addiction_NN [_NN
          27_CD ]_NN ._. Confusion_NN about_IN the_DT differences_NNS between_IN addiction_NN ,_,
          tolerance_NN ,_, and_CC physical_JJ dependence_NN is_VBZ in_IN part_NN
          responsible_JJ ._.
          The_DT hallmark_NN of_IN opioid_NN addiction_NN is_VBZ psychological_JJ
          dependence_NN manifested_JJ by_IN a_DT behavioral_JJ syndrome_NN of_IN
          continued_VBD ,_, compulsive_JJ drug_NN use_NN ,_, despite_IN harm_NN [_NN 28_CD ]_NN ._.
          Care_NNP must_MD be_VB taken_VBN to_TO differentiate_VB a_DT true_JJ addiction_NN
          (_( substance_NN use_NN disorder_NN )_) from_IN pseudo_NN addiction_NN due_JJ to_TO
          under_IN treatment_NN of_IN pain_NN or_CC other_JJ aberrant_NN drug-related_JJ
          behaviors_NNS [_NN 29_CD ]_NN ._.
          Pharmacological_NNP tolerance_NN to_TO analgesics_NNS (_( ie_NN ,_, the_DT
          reduced_VBN effectiveness_NN of_IN a_DT given_VBN dose_NN of_IN medication_NN over_IN
          time_NN )_) ,_, is_VBZ not_RB evidence_NN of_IN addiction_NN ,_, [_NN 30_CD ]_NN and_CC is_VBZ rarely_RB
          significant_JJ clinically_RB ._. After_IN an_DT initial_JJ titration_NN
          period_NN ,_, doses_NNS may_MD remain_VB stable_JJ for_IN long_JJ periods_NNS (_( months_NNS
          to_TO years_NNS )_) if_IN the_DT pain_NN stimulus_NN remains_VBZ unchanged_JJ ._. An_DT
          increasing_VBG need_NN for_IN more_JJR analgesics_NNS more_RBR likely_JJ reflects_VBZ
          progression_NN of_IN the_DT symptom_NN and_CC underlying_VBG disease_NN ._. On_IN the_DT
          other_JJ hand_NN ,_, tolerance_NN to_TO opioid_NN adverse_JJ effects_NNS is_VBZ
          commonly_RB observed_VBN ,_, and_CC is_VBZ favorable_JJ [_NN 31_CD ]_NN ._.
          Physical_JJ dependence_NN ,_, evidenced_VBN by_IN the_DT development_NN of_IN a_DT
          withdrawal_NN syndrome_NN when_WRB a_DT medication_NN is_VBZ suddenly_RB
          withdrawn_VBN ,_, is_VBZ not_RB evidence_NN of_IN addition_NN [_NN 30_CD ]_NN ._. Similar_JJ
          outcomes_NNS occur_VBP in_IN the_DT presence_NN of_IN exogenous_JJ hormones_NNS and_CC
          other_JJ medications_NNS that_WDT act_NN through_IN cellular_JJ receptors_NNS
          (_( eg_NN ,_, estrogens_NNS ,_, beta-blockers_JJ ,_, alpha-_NN 2_CD agonists_NNS ,_,
          caffeine_NN ,_, etc_FW ._. )_) ._. Some_DT patients_NNS will_MD experience_VB less_JJR pain_NN ,_,
          either_CC spontaneously_RB ,_, or_CC with_IN changes_NNS in_IN their_PRP$ underlying_VBG
          disease_NN ._. If_IN the_DT pain_NN stimulus_NN decreases_NNS or_CC disappears_VBZ ,_,
          opioid_NN doses_NNS usually_RB can_MD be_VB reduced_VBN in_IN decrements_NNS of_IN 50_CD %_NN
          or_CC more_JJR every_DT 2_CD to_TO 3_CD days_NNS ,_, and_CC finally_RB stopped_VBD without_IN
          causing_VBG a_DT withdrawal_NN syndrome_NN [_NN 32_CD ]_NN ._.
        
        
          Depression_NNP
          It_PRP is_VBZ a_DT myth_NN that_IN persistent_JJ feelings_NNS of_IN helplessness_NNS
          and_CC hopelessness_NNS are_VBP inevitable_JJ and_CC permanent_JJ
          consequences_NNS of_IN advanced_VBD life-threatening_JJ illness_NN [_NN 33_CD ]_NN
          ._. Most_JJS patients_NNS with_IN a_DT serious_JJ illness_NN experience_NN periods_NNS
          of_IN intense_JJ situational_NN sadness_NNS and_CC anxiety_NN accompanied_VBN by_IN
          depressive_JJ symptoms_NNS ._. These_DT feelings_NNS are_VBP usually_RB present_JJ
          for_IN a_DT relatively_RB short_JJ period_NN (_( days_NNS to_TO weeks_NNS )_) ,_, and_CC then_RB
          resolve_VB ._. However_RB ,_, in_IN a_DT variable_JJ number_NN of_IN patients_NNS ,_, these_DT
          feelings_NNS persist_VBP ._.
          The_DT earlier_JJR depression_NN is_VBZ diagnosed_VBN ,_, the_DT more_RBR
          responsive_JJ to_TO treatment_NN it_PRP may_MD be_VB [_NN 34_CD ]_NN ._. The_DT most_RBS
          reliable_JJ symptoms_NNS of_IN major_JJ depression_NN in_IN patients_NNS with_IN
          advanced_JJ illness_NN are_VBP persistent_JJ dysphoria_NN ,_, anhedonia_NN ,_,
          feelings_NNS of_IN helplessness_NNS ,_, hopelessness_NNS ,_, and_CC
          worthlessness_NNS ,_, and_CC loss_NN of_IN self-esteem_NN [_NN 35_CD ]_NN ._. The_DT
          somatic_JJ symptoms_NNS of_IN depression_NN (_( such_JJ as_IN changes_NNS in_IN
          weight_NN )_) are_VBP unreliable_JJ as_IN they_PRP may_MD reflect_VB the_DT underlying_VBG
          illness_NN [_NN 36_CD ]_NN ._. The_DT screening_NN question_NN ,_, "_'' Do_VBP you_PRP feel_VB
          depressed_VBN most_JJS of_IN the_DT time_NN ?_. "_'' is_VBZ a_DT highly_RB sensitive_JJ and_CC
          specific_JJ question_NN in_IN this_DT population_NN [_NN 37_CD ]_NN ._. Thoughts_NNP of_IN
          suicide_NN and_CC requests_NNS to_TO hasten_VB death_NN may_MD be_VB a_DT marker_NN of_IN
          undiagnosed_JJ depression_NN ._.
          Treatment_NNP for_IN depression_NN may_MD help_VB patients_NNS feel_VB better_JJR
          and_CC have_VBP the_DT energy_NN and_CC interest_NN to_TO achieve_VB their_PRP$ final_JJ
          goals_NNS before_IN they_PRP die_VBP ._. Approaches_NNP that_WDT combine_VBP supportive_JJ
          counseling_NN and_CC psychotherapy_NN with_IN antidepressant_NN
          medication_NN work_NN best_JJS ._. Other_JJ members_NNS of_IN the_DT health_NN care_NN
          team_NN can_MD provide_VB invaluable_JJ assistance_NN to_TO support_VB the_DT
          depressed_VBN patient_NN ,_, and_CC his_PRP$ or_CC her_PRP$ family_NN ._.
          When_WRB reversal_NN of_IN depression_NN is_VBZ an_DT immediate_JJ short-term_JJ
          goal_NN ,_, a_DT rapid-acting_JJ psychostimulant_NN (_( such_JJ as_IN
          methylphenidate_NN )_) is_VBZ the_DT best_JJS choice_NN [_NN 38_CD ]_NN ._. If_IN a_DT
          response_NN in_IN 2_CD to_TO 4_CD weeks_NNS is_VBZ acceptable_JJ ,_, an_DT atypical_JJ
          antidepressant_NN or_CC selective_JJ serotonin_NN reuptake_NN inhibitor_NN
          (_( SSRI_NNP )_) may_MD be_VB an_DT appropriate_JJ choice_NN [_NN 39_CD ]_NN ._. Tricyclic_NNP
          antidepressants_NNS have_VBP limited_JJ usefulness_NN due_JJ to_TO their_PRP$ long_JJ
          time_NN to_TO achieve_VB therapeutic_JJ levels_NNS and_CC risk_NN of_IN
          anticholinergic_JJ adverse_JJ effects_NNS [_NN 40_CD ]_NN ._. If_IN the_DT diagnosis_NN
          is_VBZ unclear_JJ ,_, or_CC the_DT expected_VBN therapeutic_JJ response_NN delayed_VBD ,_,
          consult_VB with_IN a_DT colleague_NN with_IN expertise_NN ._.
        
        
          Anxiety_NN
          Patients_NNS facing_VBG a_DT life-threatening_JJ illness_NN commonly_RB
          experience_NN anxiety_NN over_IN their_PRP$ fears_NNS and_CC uncertainties_NNS
          about_IN their_PRP$ future_JJ [_NN 41_CD ]_NN ._. Compassionate_NNP exploration_NN of_IN
          the_DT specific_JJ issues_NNS that_WDT are_VBP causing_VBG or_CC exacerbating_VBG
          anxiety_NN may_MD be_VB complex_JJ ._. Issues_NNS of_IN grief_NN and_CC loss_NN may_MD be_VB
          important_JJ contributors_NNS ._. Differentiate_NNP between_IN primary_JJ
          anxiety_NN and_CC delirium_NN ,_, depression_NN ,_, bipolar_NN disorder_NN ,_, and_CC
          medication_NN side_NN effects_NNS ._. Look_VB for_IN insomnia_NN and_CC other_JJ
          reversible_JJ causes_NNS of_IN anxiety_NN due_JJ to_TO alcohol_NN ,_, caffeine_NN ,_, or_CC
          medications_NNS [_NN 42_CD ]_NN ._. Input_NNP from_IN family_NN ,_, friends_NNS and_CC other_JJ
          members_NNS of_IN the_DT interdisciplinary_JJ team_NN may_MD be_VB
          invaluable_JJ ._.
          Like_IN depression_NN ,_, the_DT management_NN of_IN anxiety_NN often_RB
          requires_VBZ a_DT combination_NN of_IN supportive_JJ therapy_NN and_CC
          medications_NNS ._. Concerns_NNS about_IN finances_NNS ,_, family_NN conflicts_NNS ,_,
          future_JJ disability_NN ,_, dependency_NN ,_, and_CC existential_NN concerns_NNS
          will_MD not_RB resolve_VB with_IN medication_NN ._. When_WRB it_PRP appears_VBZ that_IN
          pharmacological_JJ therapy_NN will_MD be_VB beneficial_JJ ,_,
          benzodiazepines_NNS are_VBP generally_RB the_DT medication_NN class_NN of_IN
          choice_NN [_NN 43_CD ]_NN ._. Intermediate_NNP half-life_NN agents_NNS (_( eg_NN ,_,
          lorazepam_NN or_CC clonazepam_NN )_) are_VBP commonly_RB used_VBN ._.
          Benzodiazepines_NNP may_MD worsen_VB short-term_JJ memory_NN ,_,
          particularly_RB in_IN the_DT elderly_JJ ,_, or_CC cause_VB confusion_NN in_IN
          patients_NNS with_IN preexisting_VBG cognitive_JJ impairment_NN ._. A_DT few_JJ
          patients_NNS will_MD experience_VB a_DT paradoxical_JJ reaction_NN to_TO
          benzodiazepines_NNS ,_, and_CC their_PRP$ anxiety_NN will_MD get_VB worse_JJR ._. When_WRB
          discontinuing_VBG benzodiazepines_NNS ,_, taper_VB them_PRP slowly_RB to_TO
          prevent_VB rebound_NN anxiety_NN ._.
        
        
          Breathlessness_NNP (_( Dyspnea_NNP )_)
          Breathlessness_NNP may_MD be_VB one_CD of_IN the_DT most_RBS distressing_JJ
          symptoms_NNS for_IN patients_NNS ,_, families_NNS ,_, and_CC caregivers_NNS ._.
          Believing_NNP the_DT patient_NN 's_POS self_NN report_NN is_VBZ the_DT best_JJS way_NN to_TO
          assess_VB it_PRP ._. Where_WRB possible_JJ ,_, the_DT underlying_VBG cause_NN should_MD be_VB
          treated_VBN to_TO at_IN least_JJS provide_VB symptomatic_JJ relief_NN when_WRB the_DT
          burden_NN of_IN the_DT therapy_NN does_VBZ not_RB outweigh_VB the_DT benefit_NN ._.
          There_EX are_VBP 3_CD widely_RB used_VBN medical_JJ approaches_NNS for_IN the_DT
          symptomatic_JJ relief_NN of_IN breathlessness_NNS :_: oxygen_NN ,_, opioids_NNS ,_,
          and_CC anxiolytics_NNS ._. Nonpharmacological_NNP interventions_NNS may_MD
          also_RB contribute_VB significantly_RB to_TO the_DT patient_NN 's_POS and_CC
          family_NN 's_POS sense_NN of_IN well-being_NN ,_, and_CC their_PRP$ ability_NN to_TO
          cope_VB ._.
          The_DT majority_NN of_IN patients_NNS who_WP report_VBP breathlessness_NNS are_VBP
          not_RB hypoxemic_JJ ._. Measures_NNS of_IN hypoxemia_NN (_( eg_NN ,_, pulse_NN oximetry_NN ,_,
          blood_NN gas_NN determination_NN )_) do_VBP not_RB correlate_VBP with_IN the_DT
          patient_NN 's_POS self-report_JJ [_NN 44_CD 45_CD 46_CD 47_CD ]_NN ._. This_DT is_VBZ not_RB to_TO
          say_VB that_IN such_JJ measurements_NNS may_MD not_RB be_VB useful_JJ in_IN
          understanding_NN pathophysiology_NN ._. However_RB ,_, the_DT measurements_NNS
          frequently_RB do_VBP not_RB correlate_VBP with_IN symptom_NN relief_NN ._. In_IN
          addition_NN ,_, such_JJ measurements_NNS may_MD be_VB uncomfortable_JJ ,_,
          frightening_JJ and_CC /_NN or_CC expensive_JJ ,_, and_CC divert_VB the_DT focus_NN away_RB
          from_IN the_DT symptom_NN ._.
          While_IN oxygen_NN will_MD not_RB reverse_VB the_DT cause_NN of_IN the_DT
          breathlessness_NNS ,_, a_DT therapeutic_JJ trial_NN of_IN supplemental_JJ
          oxygen_NN by_IN nasal_NN prongs_NNS may_MD be_VB beneficial_JJ ._. This_DT may_MD have_VB a_DT
          placebo_NN effect_NN [_NN 47_CD ]_NN ._. In_IN addition_NN ,_, its_PRP$ effectiveness_NN
          may_MD be_VB explained_VBN by_IN the_DT observation_NN that_WDT cool_VBP air_NN moving_VBG
          across_IN the_DT patient_NN 's_POS face_NN (_( eg_NN ,_, from_IN compressed_VBN air_NN by_IN
          nasal_NN prongs_NNS ,_, or_CC from_IN a_DT fan_NN )_) may_MD provide_VB equal_JJ relief_NN due_JJ
          to_TO the_DT stimulation_NN of_IN the_DT V_NNP 2_CD branch_NN of_IN the_DT fifth_JJ cranial_NN
          nerve_NN [_NN 48_CD ]_NN ._.
          Opioids_NNP may_MD provide_VB significant_JJ relief_NN of_IN the_DT sense_NN of_IN
          breathlessness_NNS without_IN having_VBG a_DT measurable_JJ impact_NN on_IN
          their_PRP$ respiratory_JJ rate_NN or_CC blood_NN gas_NN concentrations_NNS [_NN 49_CD ]_NN
          ._. Through_IN both_DT central_JJ and_CC peripheral_JJ effects_NNS ,_, doses_NNS
          lower_JJR than_IN those_DT used_VBN to_TO relieve_VB pain_NN may_MD be_VB effective_JJ in_IN
          opioid_NN naïve_NN patients_NNS ._. In_IN some_DT patients_NNS ,_, subjective_JJ
          relief_NN may_MD also_RB be_VB associated_VBN with_IN a_DT measurable_JJ increase_NN
          in_IN exercise_NN tolerance_NN and_CC mobility_NN [_NN 50_CD 51_CD ]_NN ._.
          Concerns_NNS that_WDT opioid_NN usage_NN to_TO manage_VB symptoms_NNS will_MD
          cause_VB respiratory_JJ depression_NN or_CC hasten_VB death_NN (_( ie_NN ,_, an_DT
          unintended_JJ effect_NN )_) ,_, or_CC cause_VB addiction_NN are_VBP not_RB relevant_JJ ._.
          Opioid_NNP treatment_NN for_IN dyspnea_NN is_VBZ consistent_JJ with_IN good_JJ
          medical_JJ practice_NN ,_, ethical_JJ when_WRB the_DT intent_NN is_VBZ to_TO relieve_VB
          suffering_VBG ,_, widely_RB accepted_VBD when_WRB standard_JJ dosing_VBG
          guidelines_NNS are_VBP followed_VBN ,_, and_CC very_RB unlikely_JJ to_TO be_VB
          associated_VBN with_IN abuse_NN behaviors_NNS [_NN 52_CD ]_NN ._. As_IN with_IN pain_NN
          treatment_NN ,_, pharmacological_JJ tolerance_NN is_VBZ not_RB a_DT clinically_RB
          significant_JJ issue_NN ._.
          Some_DT patients_NNS who_WP are_VBP breathless_JJ and_CC anxious_JJ may_MD also_RB
          need_VB treatment_NN for_IN their_PRP$ anxiety_NN ._. Benzodiazepine_NNP
          medications_NNS may_MD be_VB combined_VBN safely_RB with_IN opioids_NNS [_NN 53_CD ]_NN
          ._.
        
        
          Nausea_NN /_NN Vomiting_NNP
          A_DT thorough_JJ assessment_NN of_IN the_DT etiology_NN and_CC
          pathophysiology_NN of_IN nausea_NN and_CC vomiting_NN is_VBZ crucial_JJ as_IN
          different_JJ causes_NNS will_MD require_VB very_RB different_JJ
          interventions_NNS ._. Two_CD organ_NN systems_NNS -_: the_DT gastric_JJ lining_NN of_IN
          the_DT GI_NNP tract_NN ,_, and_CC the_DT area_NN postrema_NN (_( the_DT chemoreceptor_NN
          trigger_NN zone_NN )_) ,_, the_DT vestibular_NN apparatus_NN ,_, and_CC the_DT cortex_NN
          of_IN the_DT brain_NN are_VBP important_JJ contributors_NNS [_NN 54_CD ]_NN ._.
          The_DT neurotransmitters_NNS dopamine_NN ,_, histamine_NN ,_,
          acetylcholine_NN ,_, and_CC serotonin_NN are_VBP important_JJ mediators_NNS of_IN
          this_DT symptom_NN complex_JJ ._. All_DT four_CD can_MD be_VB demonstrated_VBN in_IN the_DT
          area_NN postrema_NN ._. Although_IN all_DT are_VBP present_JJ in_IN the_DT lining_NN of_IN
          the_DT GI_NNP tract_NN ,_, serotonin_NN is_VBZ particularly_RB important_JJ ._.
          Acetylcholine_NNP and_CC histamine_NN are_VBP important_JJ in_IN the_DT
          vestibular_NN apparatus_NN ._. Nausea_NN and_CC vomiting_NN that_WDT is_VBZ
          mediated_JJ by_IN the_DT cortex_NN is_VBZ more_RBR complex_JJ and_CC not_RB associated_VBN
          with_IN specific_JJ neurotransmitters_NNS (_( eg_NN ,_, the_DT anticipatory_NN
          nausea_NN associated_VBN with_IN chemotherapy_NN )_) ._.
          Dopamine-mediated_NNP nausea_NN is_VBZ probably_RB the_DT most_RBS
          frequently_RB targeted_VBN for_IN initial_JJ symptom_NN management_NN ,_, even_RB
          when_WRB the_DT precise_JJ mechanism_NN of_IN nausea_NN is_VBZ not_RB known_VBN ._.
          Dopamine_NNP antagonist_NN medications_NNS used_VBN to_TO control_VB nausea_NN
          include_VBP the_DT phenothiazines_NNS (_( eg_NN ,_, prochlorperazine_NN )_) or_CC
          butyrophenone_NN neuroleptics_NNS (_( eg_NN ,_, haloperidol_NN )_) ._. Both_DT have_VBP
          the_DT potential_NN to_TO cause_VB drowsiness_NNS and_CC extrapyramidal_NN
          symptoms_NNS ,_, particularly_RB in_IN young_JJ women_NNS [_NN 55_CD ]_NN ._.
          Commonly_NNP used_VBD antihistamines_NNS (_( eg_NN ,_, diphenhydramine_NN ,_,
          hydroxyzine_NN )_) also_RB have_VBP anticholinergic_JJ properties_NNS ._. They_PRP
          may_MD do_VB "_'' double_JJ duty_NN "_'' as_IN a_DT single_JJ agent_NN and_CC cover_VB both_DT
          etiologies_NNS of_IN nausea_NN [_NN 56_CD ]_NN ._.
          Opioids_NNP and_CC anesthetics_NNS can_MD trigger_VB
          acetylcholine-mediated_JJ nausea_NN in_IN the_DT vestibular_NN
          apparatus_NN ._. A_DT pure_JJ anticholinergic_JJ medication_NN may_MD be_VB added_VBN
          to_TO other_JJ antiemetics_NNS in_IN empirical_JJ therapy_NN ,_, particularly_RB
          when_WRB the_DT vestibular_NN apparatus_NN is_VBZ implicated_VBN (_( eg_NN
          scopolamine_NN )_) [_NN 57_CD ]_NN ._.
          Serotonin_NNP antagonists_NNS have_VBP been_VBN very_RB effective_JJ in_IN
          treating_VBG chemotherapy-associated_JJ nausea_NN (_( eg_NN ,_, ondansetron_NN )_)
          [_NN 58_CD ]_NN ._. They_PRP have_VBP been_VBN reported_VBN to_TO be_VB useful_JJ for_IN
          refractory_JJ nausea_NN of_IN diverse_JJ types_NNS but_CC are_VBP typically_RB
          tried_VBN only_RB when_WRB other_JJ medications_NNS have_VBP failed_VBN ._. They_PRP are_VBP
          expensive_JJ and_CC should_MD be_VB promptly_RB stopped_VBN if_IN they_PRP are_VBP not_RB
          effective_JJ after_IN a_DT short_JJ therapeutic_JJ trial_NN ._.
          A_DT "_'' sluggish_JJ "_'' or_CC dyskinetic_JJ gut_NN that_WDT does_VBZ not_RB empty_VB
          properly_RB (_( due_JJ to_TO carcinomatosis_NNS ,_, opioid_NN therapy_NN ,_, other_JJ
          medications_NNS ,_, diabetes_NN mellitus_JJ etc_FW ._. )_) may_MD be_VB a_DT source_NN of_IN
          nausea_NN and_CC vomiting_NN in_IN patients_NNS with_IN advanced_JJ disease_NN [_NN
          59_CD ]_NN ._. Constipation_NNP ,_, a_DT large_JJ liver_NN producing_VBG a_DT "_'' squashed_JJ
          stomach_NN ,_, "_'' ascites_NNS ,_, or_CC peritoneal_JJ disease_NN may_MD be_VB causing_VBG
          pseudo-obstruction_JJ ._. Medications_NNP with_IN prokinetic_JJ effects_NNS
          (_( eg_NN ,_, metoclopramide_NN )_) or_CC stimulant_NN laxatives_NNS (_( eg_NN ,_, senna_NN ,_,
          bisacodyl_NN )_) may_MD be_VB effective_JJ at_IN moving_VBG gut_NN contents_NNS
          forward_RB ,_, and_CC relieving_VBG the_DT associated_VBN nausea_NN [_NN 60_CD ]_NN ._.
          Hyperacidity_NNP ,_, with_IN or_CC without_IN gastroesophageal_NN reflux_NN
          and_CC /_NN or_CC gastric_JJ or_CC duodenal_JJ erosions_NNS ,_, may_MD produce_VB nausea_NN ,_,
          heartburn_NN ,_, acidity_NN ,_, or_CC bitter_JJ taste_NN that_WDT may_MD be_VB
          associated_VBN with_IN vomiting_NN ._. Antacids_NNP ,_, H_NNP 
          2_CD receptor_NN antagonists_NNS ,_, or_CC proton_NN pump_NN
          inhibitors_NNS may_MD relieve_VB the_DT hyperacidity_NN and_CC /_NN or_CC reflux_NN ._.
          Cytoprotective_NNP agents_NNS (_( eg_NN ,_, misoprostol_NN )_) may_MD be_VB effective_JJ
          in_IN treating_VBG the_DT nausea_NN associated_VBN with_IN mucosal_NN erosion_NN
          secondary_JJ to_TO NSAIDs_NNP ._.
          Heterogeneous_NNP groups_NNS of_IN medications_NNS that_WDT have_VBP unclear_JJ
          mechanisms_NNS of_IN action_NN ,_, but_CC uncontested_JJ benefits_NNS in_IN some_DT
          patients_NNS include_VBP glucocorticoids_NNS (_( eg_NN ,_, dexamethasone_NN )_) ,_,
          cannabinoids_NNS (_( eg_NN ,_, tetrahydrocannabinol_NN )_) ,_, and_CC
          benzodiazepines_NNS (_( eg_NN ,_, lorazepam_NN )_) [_NN 61_CD 62_CD 63_CD ]_NN ._.
          With_IN complete_JJ obstruction_NN ,_, accumulation_NN of_IN
          intraluminal_NN fluid_JJ from_IN epithelial_NN sources_NNS is_VBZ principally_RB
          responsible_JJ for_IN the_DT symptoms_NNS of_IN bloating_VBG ,_, crampy_NN
          abdominal_NN pain_NN ,_, nausea_NN ,_, and_CC vomiting_NN ._. Octreotide_NNP ,_, a_DT
          synthetic_JJ analog_NN of_IN somatostatin_NN ,_, selectively_RB inhibits_NNS
          secretion_NN of_IN fluids_NNS and_CC electrolytes_NNS into_IN the_DT gut_NN lumen_NN
          and_CC may_MD relieve_VB these_DT symptoms_NNS [_NN 64_CD 65_CD 66_CD ]_NN ._.
          Refractory_NNP cases_NNS of_IN nausea_NN and_CC vomiting_NN often_RB require_VB
          combinations_NNS of_IN medications_NNS from_IN different_JJ classes_NNS ._.
        
        
          Constipation_NNP
          Constipation_NNP is_VBZ "_'' the_DT discomfort_NN associated_VBN with_IN
          reduced_VBN frequency_NN of_IN bowel_NN movements_NNS "_'' [_NN 67_CD ]_NN ._. If_IN left_VBD
          unmanaged_JJ ,_, it_PRP can_MD lead_VB to_TO abdominal_NN pain_NN ,_, bloating_VBG ,_,
          nausea_NN and_CC vomiting_NN ,_, overflow_NN incontinence_NN ,_, tenesmus_JJ ,_,
          fecal_JJ impaction_NN ,_, or_CC even_RB bowel_NN obstruction_NN ._.
          As_IN there_EX is_VBZ a_DT wide_JJ range_NN of_IN "_'' normal_JJ "_'' in_IN bowel_NN habits_NNS ,_,
          begin_VB by_IN assessing_VBG what_WP the_DT patient_NN considers_VBZ normal_JJ
          bowel_NN function_NN ._. Tailor_NNP examination_NN ,_, investigation_NN ,_, and_CC
          treatment_NN to_TO the_DT presentation_NN ,_, stage_NN ,_, and_CC context_NN of_IN the_DT
          person_NN and_CC illness_NN ._. For_IN most_JJS patients_NNS near_IN the_DT end_NN of_IN
          life_NN ,_, correction_NN of_IN the_DT underlying_VBG pathophysiological_JJ
          cause_NN of_IN constipation_NN is_VBZ often_RB not_RB possible_JJ or_CC
          appropriate_JJ ._. Constipation_NNP should_MD be_VB expected_VBN during_IN
          opioid_NN treatment_NN and_CC prophylactic_JJ measures_NNS always_RB be_VB
          initiated_VBN from_IN the_DT outset_NN as_IN the_DT condition_NN is_VBZ easier_JJR to_TO
          prevent_VB than_IN treat_VB [_NN 68_CD ]_NN ._. Opioids_NNP cause_VB constipation_NN ,_,
          but_CC they_PRP are_VBP not_RB the_DT only_JJ medication_NN to_TO do_VB so_RB ._. Other_JJ
          medications_NNS that_WDT may_MD cause_VB or_CC exacerbate_VB the_DT problem_NN are_VBP
          those_DT with_IN anticholinergic_JJ adverse_JJ effects_NNS (_( eg_NN ,_, tricyclic_JJ
          antidepressants_NNS )_) and_CC calcium-channel_JJ blockers_NNS (_( eg_NN
          verapamil_NN )_) ._.
          As_IN a_DT general_JJ measure_NN ,_, have_VBP the_DT patient_NN toilet_NN
          regularly_RB at_IN the_DT same_JJ time_NN each_DT day_NN ._. Take_VB advantage_NN of_IN
          the_DT gastrocolic_JJ reflex_JJ that_WDT occurs_VBZ after_IN eating_VBG -_: the_DT
          strongest_JJS peristalsis_NNS occurs_VBZ in_IN the_DT early_JJ morning_NN [_NN 69_CD ]_NN
          ._.
          Cathartic_NNP medications_NNS fall_VBP into_IN several_JJ classes_NNS [_NN 70_CD ]_NN
          ._. For_IN patients_NNS with_IN advanced_JJ illness_NN ,_, poor_JJ mobility_NN ,_, and_CC
          decreased_VBD oral_JJ intake_NN ,_, a_DT stimulant_NN laxative_NN (_( eg_NN ,_, prune_VB
          juice_NN ,_, senna_NN ,_, casanthranol_NN ,_, or_CC bisacodyl_NN )_) is_VBZ appropriate_JJ
          front-line_JJ therapy_NN [_NN 71_CD ]_NN ._. Osmotic_NNP laxatives_NNS (_( eg_NN ,_,
          magnesium_NN salts_NNS ,_, lactulose_NN ,_, sorbitol_NN )_) may_MD be_VB added_VBN ._.
          Detergent_NNP laxatives_NNS (_( eg_NN ,_, docusate_NN )_) at_IN conventional_JJ doses_NNS
          are_VBP only_RB stool_NN softeners_NNS ,_, and_CC are_VBP rarely_RB effective_JJ when_WRB
          used_VBN alone_RB for_IN patients_NNS at_IN the_DT end-of-life_JJ ._. Prokinetic_NNP
          agents_NNS (_( eg_NN ,_, metoclopramide_NN )_) added_VBD to_TO the_DT regimen_NN may_MD
          assist_VB the_DT occasional_JJ patient_NN whose_WP$ constipation_NN is_VBZ
          refractory_JJ ._. A_DT lubricant_NN stimulant_NN (_( eg_NN ,_, mineral_NN oil_NN )_) may_MD
          assist_VB a_DT patient_NN to_TO defecate_NN if_IN the_DT rectal_NN vault_NN is_VBZ full_JJ ._.
          Large-volume_NNP enemas_NNS that_WDT work_NN by_IN distending_VBG the_DT colon_NN to_TO
          induce_VB peristalsis_NNS and_CC soften_VB are_VBP not_RB well_RB tolerated_JJ by_IN
          debilitated_JJ patients_NNS ._.
          A_DT frequent_JJ mistake_NN is_VBZ the_DT failure_NN to_TO dose-escalate_JJ a_DT
          particular_JJ cathartic_JJ ._. This_DT leads_VBZ to_TO the_DT sense_NN that_IN
          "_'' nothing_NN works_VBZ "_'' when_WRB ,_, in_IN fact_NN ,_, nothing_NN has_VBZ been_VBN tried_VBN to_TO
          its_PRP$ maximal_NN therapeutic_JJ dose_NN ._. Habituation_NNP in_IN patients_NNS at_IN
          the_DT end-of-life_JJ is_VBZ rarely_RB an_DT important_JJ clinical_JJ
          concern_NN ._.
        
        
          Fatigue_NNP /_NN Weakness_NN
          Fatigue_NNP /_NN weakness_NN is_VBZ the_DT most_RBS frequent_JJ distressing_JJ
          symptom_NN associated_VBN with_IN advanced_JJ illness_NN and_CC end-of-life_JJ
          care_NN ._. Patients_NNS and_CC families_NNS frequently_RB focus_VBP on_IN the_DT
          symptom_NN rather_RB than_IN its_PRP$ underlying_VBG cause_NN ._. Many_JJ believe_VBP
          that_IN a_DT person_NN 's_POS strength_NN is_VBZ under_IN his_PRP$ or_CC her_PRP$ control_NN ,_, and_CC
          feel_VBP that_IN the_DT patient_NN is_VBZ "_'' giving_VBG up_RP ,_, "_'' "_'' not_RB fighting_VBG ,_, "_'' or_CC
          "_'' not_RB eating_VBG enough_RB ._. "_''
          Physicians_NNPS can_MD play_VB an_DT instrumental_JJ role_NN by_IN educating_VBG
          patients_NNS and_CC families_NNS about_IN the_DT nature_NN of_IN the_DT symptom_NN ,_,
          and_CC by_IN giving_VBG the_DT patient_NN "_'' permission_NN "_'' to_TO rest_VB ._. They_PRP can_MD
          help_VB decrease_VB the_DT pressure_NN from_IN family_NN or_CC others_NNS
          exhorting_VBG the_DT patient_NN to_TO be_VB more_JJR alert_NN ,_, energetic_JJ ,_, and_CC
          conversant_NN ._. Assistance_NNP from_IN other_JJ team_NN members_NNS may_MD be_VB
          instrumental_JJ ._.
          There_EX are_VBP many_JJ general_JJ approaches_NNS to_TO the_DT management_NN of_IN
          fatigue_NN [_NN 69_CD ]_NN ._. Help_VB patients_NNS and_CC families_NNS to_TO adapt_VB
          activities_NNS of_IN daily_JJ living_NN to_TO promote_VB energy_NN
          conservation_NN ._. Physiotherapy_NNP and_CC occupational_NN therapy_NN can_MD
          help_VB with_IN assessment_NN ,_, teaching_NN ,_, and_CC assistive_JJ devices_NNS ._.
          Discontinue_NNP routine_JJ medications_NNS that_WDT are_VBP no_DT longer_RB
          appropriate_JJ near_IN the_DT end_NN of_IN life_NN that_WDT may_MD be_VB making_VBG the_DT
          fatigue_NN worse_JJR (_( eg_NN ,_, antihypertensives_NNS ,_, cardiac_JJ
          medications_NNS ,_, diuretics_NNS ,_, etc_FW ._. )_) ._.
          While_IN fatigue_NN /_NN weakness_NN is_VBZ not_RB easily_RB treated_VBN
          pharmacologically_RB ,_, some_DT patients_NNS respond_VBP to_TO
          glucocorticoids_NNS (_( eg_NN ,_, dexamethasone_NN )_) [_NN 70_CD 71_CD 72_CD ]_NN ._. While_IN
          they_PRP can_MD be_VB continued_VBN until_IN death_NN ,_, the_DT effect_NN may_MD wane_VB
          after_IN 4_CD to_TO 6_CD weeks_NNS ._. As_IN long-term_JJ adverse_JJ effects_NNS are_VBP not_RB
          a_DT factor_NN for_IN patients_NNS who_WP are_VBP at_IN the_DT end_NN of_IN their_PRP$ lives_NNS ,_,
          there_EX is_VBZ no_DT need_VBP to_TO taper_VB the_DT dose_NN if_IN it_PRP remains_VBZ
          effective_JJ ._. The_DT psychostimulants_NNS (_( eg_NN ,_, methylphenidate_NN )_) may_MD
          also_RB be_VB effective_JJ [_NN 73_CD ]_NN ._.
        
        
          Symptom_NNP Management_NNP During_IN The_DT Last_JJ Hours_NNS Of_IN
          Life_NNP
          There_EX are_VBP a_DT variety_NN of_IN physiological_JJ changes_NNS that_WDT
          occur_VBP in_IN the_DT last_JJ hours_NNS and_CC days_NNS of_IN life_NN ._. Each_DT can_MD be_VB
          alarming_JJ if_IN it_PRP is_VBZ not_RB understood_VBN ._. The_DT most_RBS common_JJ are_VBP
          summarized_VBD here_RB ._.
        
        
          Weakness_NN and_CC Fatigue_NNP
          Weakness_NN and_CC fatigue_NN usually_RB increase_NN as_IN the_DT patient_NN
          approaches_NNS death_NN ._. The_DT patients_NNS may_MD become_VB almost_RB
          completely_RB still_RB ,_, and_CC this_DT need_MD not_RB be_VB resisted_VBN ._. Most_JJS
          treatment_NN to_TO alleviate_VB it_PRP can_MD be_VB discontinued_VBN ._. Joints_NNP may_MD
          become_VB uncomfortable_JJ if_IN they_PRP are_VBP not_RB moved_VBN [_NN 77_CD ]_NN ._.
          Continuous_NNP pressure_NN on_IN the_DT same_JJ area_NN of_IN skin_NN ,_,
          particularly_RB over_IN bony_NN prominences_NNS ,_, will_MD increase_VB the_DT
          risk_NN of_IN skin_NN ischemia_NN ,_, and_CC pain_NN [_NN 78_CD ]_NN ._. As_IN the_DT patient_NN
          approaches_NNS death_NN ,_, provide_VB adequate_JJ support_NN and_CC cushioning_NN
          on_IN the_DT bed_NN to_TO lessen_VB the_DT need_NN for_IN uncomfortable_JJ
          turning_NN ._.
        
        
          Cessation_NNP of_IN Intake_NNP
          Most_JJS patients_NNS completely_RB lose_VBP their_PRP$ appetite_NN and_CC stop_VB
          drinking_NN [_NN 79_CD 80_CD ]_NN ._. This_DT may_MD heighten_VB onlookers_NNS '_POS
          distress_NN ._. However_RB ,_, most_JJS experts_NNS feel_VBP that_DT dehydration_NN in_IN
          the_DT last_JJ hours_NNS of_IN living_NN does_VBZ not_RB cause_VB distress_NN and_CC may_MD
          stimulate_VB the_DT release_NN of_IN endorphins_NNS and_CC anaesthetic_JJ
          compounds_NNS that_WDT promote_VBP the_DT patient_NN 's_POS sense_NN of_IN well_RB being_VBG
          [_NN 81_CD 82_CD 83_CD ]_NN ._. Low_NNP blood_NN pressure_NN or_CC weak_JJ pulse_NN is_VBZ part_NN
          of_IN the_DT dying_VBG process_NN and_CC not_RB an_DT indication_NN of_IN
          dehydration_NN ._. Patients_NNS who_WP are_VBP not_RB able_JJ to_TO be_VB upright_NN do_VBP
          not_RB get_VB light-headed_JJ or_CC dizzy_NN ._. Meticulous_NNP oral_JJ ,_, nasal_NN ,_,
          and_CC conjunctival_NN hygiene_NN help_NN to_TO allay_VB concerns_NNS overt_JJ
          patient_NN thirst_NN [_NN 84_CD ]_NN ._.
          Patients_NNS with_IN peripheral_JJ edema_NN or_CC ascites_NNS have_VBP excess_JJ
          body_NN water_NN and_CC salt_NN and_CC are_VBP not_RB dehydrated_JJ ,_, though_IN their_PRP$
          intravascular_NN volume_NN may_MD be_VB contracted_VBN due_JJ to_TO
          hypoalbuminemia_NN ._. Parenteral_NNP fluids_NNS ,_, delivered_VBN either_CC
          intravenously_RB or_CC subcutaneously_RB by_IN hypodermoclysis_NNS ,_, are_VBP
          sometimes_RB considered_VBN ,_, particularly_RB when_WRB the_DT goal_NN is_VBZ to_TO
          reverse_VB delirium_NN [_NN 85_CD ]_NN ._. However_RB ,_, parenteral_NN fluids_NNS may_MD
          have_VB adverse_JJ effects_NNS that_WDT are_VBP not_RB commonly_RB considered_VBN ._.
          Intravenous_NNP lines_NNS can_MD be_VB cumbersome_JJ and_CC particularly_RB
          uncomfortable_JJ when_WRB the_DT patient_NN is_VBZ cachectic_JJ ,_, or_CC has_VBZ no_DT
          discernible_JJ veins_NNS ._. Excess_NNP parenteral_NN fluids_NNS can_MD lead_VB to_TO
          fluid_JJ overload_NN with_IN consequent_JJ peripheral_JJ or_CC pulmonary_JJ
          edema_NN ,_, worsened_VBN breathlessness_NNS ,_, cough_NN ,_, and_CC
          orotracheobronchial_NN secretions_NNS ,_, particularly_RB if_IN there_EX is_VBZ
          significant_JJ hypoalbuminemia_NN ._.
        
        
          Loss_NN of_IN Ability_NNP to_TO Swallow_NNP
          Once_RB the_DT patient_NN is_VBZ unable_JJ to_TO swallow_VB ,_, cease_VB oral_JJ
          intake_NN ._. Warn_NNP families_NNS and_CC professional_JJ caregivers_NNS of_IN the_DT
          risk_NN of_IN aspiration_NN ._. Scopolamine_NNP or_CC glycopyrrolate_NN will_MD
          effectively_RB reduce_VB the_DT production_NN of_IN saliva_NN and_CC other_JJ
          secretions_NNS [_NN 37_CD 38_CD ]_NN ._. They_PRP will_MD minimize_VB or_CC eliminate_VB
          the_DT gurgling_VBG from_IN mucous_JJ buildup_NN in_IN the_DT pharynx_NN and_CC
          trachea_NN and_CC may_MD be_VB used_VBN prophylactically_RB in_IN the_DT
          unconscious_JJ dying_VBG patient_NN ._. Anecdote_NNP suggests_VBZ that_IN the_DT
          earlier_JJR treatment_NN is_VBZ initiated_VBN ,_, the_DT better_JJR it_PRP works_VBZ ,_, as_IN
          larger_JJR amounts_NNS of_IN secretions_NNS in_IN the_DT upper_JJ aerodigestive_JJ
          tract_NN are_VBP more_RBR difficult_JJ to_TO eliminate_VB ._. However_RB ,_, premature_JJ
          use_NN in_IN the_DT patient_NN who_WP is_VBZ still_RB alert_VB may_MD lead_VB to_TO
          unacceptable_JJ drying_VBG of_IN oral_JJ and_CC pharyngeal_NN mucosa_NN ._. While_IN
          atropine_NN may_MD be_VB equally_RB effective_JJ ,_, it_PRP has_VBZ an_DT increased_VBN
          risk_NN of_IN producing_VBG undesired_JJ cardiac_JJ and_CC /_NN or_CC CNS_NNP excitation_NN
          [_NN 86_CD ]_NN ._.
          If_IN excessive_JJ fluid_JJ accumulates_NNS in_IN the_DT back_NN of_IN the_DT
          throat_NN and_CC upper_JJ airways_NNS ,_, it_PRP may_MD be_VB cleared_VBN by_IN
          repositioning_NN or_CC postural_NN drainage_NN ._. Oropharyngeal_NNP
          suctioning_VBG is_VBZ likely_JJ to_TO be_VB ineffective_JJ as_IN secretions_NNS are_VBP
          usually_RB beyond_IN the_DT reach_NN of_IN the_DT catheter_NN ._. Continued_VBN
          efforts_NNS to_TO suction_NN may_MD only_RB stimulate_VB an_DT otherwise_RB
          peaceful_JJ patient_NN ,_, and_CC distress_NN family_NN members_NNS who_WP are_VBP
          watching_VBG ._.
        
        
          Neurological_NNP Changes_NNS
          The_DT neurological_JJ changes_NNS associated_VBN with_IN the_DT dying_VBG
          process_NN are_VBP the_DT result_NN of_IN multiple_JJ concurrent_JJ
          irreversible_JJ factors_NNS ._. These_DT changes_NNS may_MD manifest_JJ
          themselves_PRP in_IN 2_CD different_JJ patterns_NNS that_WDT have_VBP been_VBN
          described_VBN as_RB the_DT "_'' two_CD roads_NNS to_TO death_NN "_'' (_( See_VB figure_NN 3_LS )_) [_NN 87_CD
          ]_NN ._. Most_JJS patients_NNS follow_VBP the_DT "_'' usual_JJ road_NN "_'' that_WDT presents_VBZ
          as_IN decreasing_VBG level_NN of_IN consciousness_NN and_CC leads_VBZ to_TO coma_NN
          and_CC death_NN ._.
        
        
          Terminal_NNP Delirium_NNP
          An_DT agitated_VBN delirium_NN may_MD be_VB the_DT first_JJ sign_NN to_TO herald_VB
          the_DT "_'' difficult_JJ road_NN to_TO death_NN ._. "_'' These_DT patients_NNS frequently_RB
          present_VBP with_IN confusion_NN ,_, restlessness_NNS ,_, and_CC /_NN or_CC agitation_NN ,_,
          with_IN or_CC without_IN day-night_JJ reversal_NN [_NN 88_CD ]_NN ._. To_TO the_DT family_NN
          and_CC professional_JJ caregivers_NNS who_WP do_VBP not_RB understand_VB it_PRP ,_,
          agitated_VBN terminal_NN delirium_NN can_MD be_VB very_RB distressing_JJ ._.
          Although_IN previous_JJ care_NN may_MD have_VB been_VBN excellent_JJ ,_, if_IN the_DT
          delirium_NN goes_VBZ misdiagnosed_JJ or_CC unmanaged_JJ ,_, family_NN members_NNS
          will_MD likely_RB remember_VB a_DT horrible_JJ death_NN "_'' in_IN terrible_JJ pain_NN "_''
          with_IN cognitive_JJ impairment_NN "_'' because_IN of_IN the_DT drugs_NNS ._. "_''
          It_PRP may_MD be_VB appropriate_JJ to_TO evaluate_VB and_CC try_VB to_TO reverse_VB
          treatable_JJ contributing_VBG factors_NNS ._. However_RB ,_, if_IN the_DT patient_NN
          is_VBZ in_IN the_DT last_JJ hours_NNS of_IN his_PRP$ or_CC her_PRP$ life_NN with_IN other_JJ
          concurrent_JJ signs_NNS of_IN the_DT dying_VBG process_NN ,_, the_DT condition_NN is_VBZ
          by_IN definition_NN irreversible_JJ ._. Management_NNP appropriately_RB
          focuses_VBZ on_IN the_DT management_NN of_IN the_DT symptoms_NNS associated_VBN with_IN
          the_DT terminal_NN delirium_NN in_IN order_NN to_TO settle_VB the_DT patient_NN and_CC
          the_DT family_NN [_NN 89_CD ]_NN ._.
          When_WRB moaning_VBG ,_, groaning_VBG ,_, and_CC grimacing_VBG accompany_VB the_DT
          agitation_NN and_CC restlessness_NNS ,_, they_PRP are_VBP frequently_RB
          interpreted_VBN as_IN physical_JJ pain_NN (_( 90_CD )_) ._. However_RB ,_,
          uncontrollable_JJ pain_NN rarely_RB develops_VBZ or_CC worsens_NNS during_IN the_DT
          last_JJ hours_NNS of_IN life_NN ._. Look_VB for_IN tension_NN in_IN the_DT forehead_NN ,_,
          particularly_RB for_IN furrowing_VBG of_IN the_DT brow_NN ,_, as_IN a_DT clue_NN that_DT
          pain_NN may_MD be_VB present_JJ ._.
          While_IN a_DT trial_NN of_IN opioids_NNS may_MD be_VB beneficial_JJ in_IN the_DT
          unconscious_JJ patient_NN who_WP is_VBZ difficult_JJ to_TO assess_VB ,_,
          physicians_NNS must_MD remember_VB that_IN opioids_NNS may_MD accumulate_VBP and_CC
          add_VB to_TO delirium_NN when_WRB renal_JJ clearance_NN is_VBZ poor_JJ [_NN 91_CD 92_CD ]_NN ._.
          If_IN the_DT trial_NN of_IN increased_VBN opioids_NNS does_VBZ not_RB relieve_VB the_DT
          agitation_NN ,_, or_CC makes_VBZ the_DT delirium_NN worse_JJR by_IN increasing_VBG
          agitation_NN or_CC precipitating_VBG myoclonic_JJ jerks_NNS or_CC seizures_NNS
          (_( rare_JJ )_) ,_, then_RB pursue_VB alternate_JJ therapies_NNS directed_VBN at_IN
          suppressing_VBG the_DT symptoms_NNS associated_VBN with_IN delirium_NN ._.
          Benzodiazepines_NNP are_VBP used_VBN widely_RB to_TO treat_VB terminal_NN
          delirium_NN as_IN they_PRP are_VBP anxiolytics_NNS ,_, amnestics_NNS ,_, skeletal_NN
          muscle_NN relaxants_NNS ,_, and_CC antiepileptics_NNS [_NN 93_CD ]_NN ._.
          Pre-dissolved_NNP oral_JJ lorazepam_NN can_MD be_VB administered_VBN against_IN
          the_DT buccal_NN mucosa_NN and_CC dose_NN escalated_VBN to_TO effect_VB ._.
          Infusional_NNP benzodiazepines_NNS may_MD be_VB a_DT rapidly_RB effective_JJ
          alternative_NN ._.
          Benzodiazepines_NNP may_MD paradoxically_RB excite_VB some_DT patients_NNS
          [_NN 94_CD ]_NN ._. These_DT patients_NNS require_VBP neuroleptic_JJ medications_NNS
          to_TO control_VB their_PRP$ delirium_NN ._. Haloperidol_NNP given_VBN
          intravenously_RB ,_, subcutaneously_RB ,_, or_CC rectally_RB may_MD be_VB
          effective_JJ [_NN 95_CD ]_NN ._. A_DT more_JJR sedating_VBG alternative_NN is_VBZ
          chlorpromazine_NN given_VBN intravenously_RB or_CC rectally_RB [_NN 96_CD ]_NN ._.
          Barbiturates_NNP or_CC propofol_NN have_VBP been_VBN suggested_VBN as_IN
          alternatives_NNS for_IN the_DT patient_NN who_WP is_VBZ particularly_RB
          difficult_JJ to_TO control_VB [_NN 97_CD 98_CD ]_NN ._.
        
        
          Family_NNP Suffering_VBG Over_IN Physiological_NNP Changes_NNS
          Changes_NNS in_IN breathing_VBG patterns_NNS are_VBP frequent_JJ and_CC can_MD be_VB
          distressing_JJ to_TO the_DT onlooker_NN ._. Warn_NNP family_NN members_NNS and_CC
          caregivers_NNS about_IN the_DT breathing_VBG patterns_NNS that_IN they_PRP may_MD
          observe_VB ._.
          Loss_NN of_IN sphincter_NN control_NN in_IN the_DT last_JJ hours_NNS of_IN life_NN
          may_MD lead_VB to_TO incontinence_NN of_IN urine_NN and_CC /_NN or_CC stool_NN ._. Cleaning_VBG
          and_CC skin_NN care_NN are_VBP important_JJ ._. A_DT urinary_JJ catheter_NN may_MD
          minimize_VB the_DT need_NN for_IN frequent_JJ changing_NN and_CC cleaning_VBG ,_,
          prevent_VB skin_NN breakdown_NN ,_, and_CC reduce_VB the_DT demand_NN on_IN
          caregivers_NNS ._. However_RB ,_, it_PRP is_VBZ not_RB always_RB necessary_JJ if_IN urine_NN
          flow_NN is_VBZ minimal_JJ and_CC can_MD be_VB managed_VBN with_IN absorbent_JJ pads_NNS or_CC
          surfaces_VBZ ._. If_IN diarrhea_NN is_VBZ considerable_JJ and_CC relentless_JJ ,_, a_DT
          rectal_NN tube_NN may_MD be_VB similarly_RB effective_JJ ._.
          Eyes_NNS that_WDT remain_VBP open_NN can_MD be_VB distressing_JJ to_TO onlookers_NNS
          unless_IN the_DT condition_NN is_VBZ understood_VBN ._. Advanced_NNP wasting_NN
          leads_VBZ to_TO loss_NN of_IN the_DT retro-orbital_JJ fat_JJ pad_NN ,_, and_CC the_DT orbit_NN
          falls_VBZ posteriorly_RB within_IN the_DT orbital_NN socket_NN [_NN 99_CD ]_NN ._. As_IN
          eyelids_NNS are_VBP of_IN insufficient_JJ length_NN to_TO both_DT extend_VB the_DT
          additional_JJ distance_NN backward_RB and_CC cover_VB the_DT conjunctiva_NN ,_,
          they_PRP may_MD not_RB be_VB able_JJ to_TO fully_RB appose_NN ._. Maintain_VBP moisture_NN
          by_IN using_VBG ophthalmic_JJ lubricants_NNS ,_, artificial_JJ tears_NNS ,_, or_CC
          physiological_JJ saline_NN [_NN 100_CD ]_NN ._.
        
      
      
        Conclusions_NNP
        A_DT host_NN of_IN physical_JJ symptoms_NNS are_VBP common_JJ in_IN patients_NNS with_IN
        advanced_VBD life-threatening_JJ illness_NN ._. If_IN assessed_VBN ,_, many_JJ can_MD be_VB
        relieved_VBN ._. We_PRP have_VBP summarized_VBD the_DT management_NN of_IN only_RB a_DT few_JJ ._.
        The_DT interested_JJ physician_NN will_MD want_VB to_TO seek_VB additional_JJ
        advice_NN from_IN some_DT of_IN the_DT many_JJ sources_NNS of_IN information_NN
        available_JJ ._. Symptom_NNP control_NN is_VBZ an_DT essential_JJ ,_, but_CC not_RB a_DT
        complete_JJ ,_, part_NN of_IN the_DT core_NN competencies_NNS of_IN physicians_NNS in_IN
        end-of-life_JJ care_NN [_NN 3_CD ]_NN ._.
      
      
        Competing_VBG Interests_NNP
        None_NN declared_VBD
      
      
        Authors_NNP '_'' Contributions_NNP
        LE_NNP conceived_VBD of_IN the_DT EPEC_NNP Program_NNP ._. FF_NNP ,_, CvG_NNP and_CC LE_NNP
        participated_VBD in_IN the_DT preparation_NN of_IN the_DT current_JJ manuscript_NN ._.
        All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
